CD20-directed Cytolytic Antibody [EPC]

124119 reported adverse events

Drugs of this class: OFATUMUMAB OBINUTUZUMAB OCRELIZUMAB RITUXIMAB RITUXIMAB AND HYALURONIDASE RITUXIMAB-ABBS RITUXIMAB-ARRX RITUXIMAB-PVVR

These side effects are most commonly reported by patients taking drugs of the CD20-directed Cytolytic Antibody [EPC] class:

# Side effect Count
0 DRUG INEFFECTIVE 17243
1 OFF LABEL USE 9581
2 RHEUMATOID ARTHRITIS 8858
3 FATIGUE 8024
4 PAIN 6813
5 NAUSEA 5882
6 PNEUMONIA 5610
7 PYREXIA 5538
8 NEUTROPENIA 5127
9 ARTHRALGIA 5061
See all common reactions for CD20-directed Cytolytic Antibody [EPC]

Drugs of the CD20-directed Cytolytic Antibody [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 CHRONIC LYMPHOCYTIC LEUKAEMIA RECURRENT 298 0.7028
1 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE 572 0.6560
2 RED BLOOD CELL SEDIMENTATION RATE 69 0.6389
3 B-CELL LYMPHOMA RECURRENT 239 0.6323
4 MANTLE CELL LYMPHOMA RECURRENT 113 0.6313
5 DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY 159 0.6260
6 PEMPHIGUS 1674 0.6000
7 DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT 447 0.5738
8 LYMPHOMA TRANSFORMATION 80 0.5517
9 GRANULOMA SKIN 231 0.5347
See all enriched reactions for CD20-directed Cytolytic Antibody [EPC]